Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Tetzlaff

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Discovery|October 4, 2018
Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell MotilityAmanpreet Kaur, Brett L Ecker, Stephen M Douglass, et al.
Cancer Discovery|April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and ImmunityIsabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
The American Journal of Surgical Pathology|November 10, 2021
Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid NeoplasmsSarah Benton, Jeffrey Zhao, Bin Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Discovery|October 4, 2018
Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell MotilityAmanpreet Kaur, Brett L Ecker, Stephen M Douglass, et al.
Cancer Discovery|April 8, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and ImmunityIsabella C Glitza, Yongwoo David Seo, Christine N Spencer, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
The American Journal of Surgical Pathology|November 10, 2021
Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid NeoplasmsSarah Benton, Jeffrey Zhao, Bin Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Oncoimmunology|November 15, 2021
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanomaMichael G White, Robert Szczepaniak Sloane, Russell G Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Pageof 23